Clinical Trial: MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Share this article:
Clinical Trial: MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Sponsor and Collaborators

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Principal Investigator
Eric Jonasch, MD M.D. Anderson Cancer Center

ClinicalTrials.gov Identifier

NCT01239342
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs